Cost-effectiveness analyses of anti-hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan.

Terumi KaishimaTomoyuki AkitaMasayuki OhisaKazuaki SakamuneAkemi KurisuAya SugiyamaHiroshi AikataKazuaki ChayamaJunko Tanaka

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)

Direct-acting antiviral treatment was estimated to be cost-effective from 10 to 25 years after treatment, depending on the SVR rate of the drugs and the age of onset of treatment. In order to increase the cost-effectiveness of DAA treatment, measures or effort to improve the QOL score of patients after SVR are necessary.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
human immunodeficiency virus
prognostic factors
antiretroviral therapy